Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.

Fundamental & clinical pharmacology - 1 Feb 2004

Damy Thibaud, Pousset Françoise, Caplain Henri, Hulot Jean-Sébastien, Lechat Philippe

Abstract excerpt

As dronedarone a new noniodinated antiarrhythmic agent structurally related to amiodarone could inhibit CYP2D6 and is planned to be associated with beta-blockers, interactions with CYP2D6 metabolized beta-blockers such as metoprolol, have to be studied. Forty-nine healthy male subjects genotyped for CYP2D6 were included in a randomized, double-blind, placebo-controlled study. Metoprolol was administrated during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Drug Interactions

Share to Echocardiography

Share to Heart Rate

Share to Hemodynamics

Share to Metoprolol

Source

Identifiers

PMID: 14748763
DOI: 10.1046/j.1472-8206.2003.00216.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.PMID 14748763Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.Semantic proximity Read ↗

In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.Semantic proximity Read ↗

[Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].Semantic proximity Read ↗

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.Semantic proximity Read ↗

Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women.Semantic proximity Read ↗

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.Semantic proximity Read ↗

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.Semantic proximity Read ↗

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.